Are Biosimilars The Next Big Opportunity In India?
This article was originally published in PharmAsia News
MUMBAI - The Indian biosimilars market is a multi-billion dollar opportunity for Indian and multinational companies to tap into, albeit via different routes, according to a white paper released this month by global consultancy Frost & Sullivan
You may also be interested in...
Biocon Chairman Kiran Mazumdar-Shaw On Hopes For An Oral Diabetes Drug, And Risks And Rewards Of Innovation: An Interview with PharmAsia News
Biocon Chairman And Managing Director Kiran Mazumdar-Shaw shares her business development strategy and newest pipeline developments with PharmAsia News in an exclusive interview.
With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim
MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry
MUMBAI - The keenly watched "Union Budget" of the Indian government made no direct references or moves that could benefit the Indian pharmaceutical industry - leaving most senior level executives disappointed and hoping for progressive steps in the future